Age-Related Macular Degeneration Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Pages: 115 Published: July 29, 2022 Report Code: GDHC246PIDR

The Age-Related Macular Degeneration (AMD) market size was valued at $7.3 billion across the 7MM in 2021. The market is expected to grow at a CAGR of more than 11% during the forecast period. AMD is one of the leading causes of irreversible vision loss.  No definitive cause of AMD has been established although advanced age, a family history of AMD, systemic conditions such as hypercholesterolemia and obesity, and lifestyle factors such as smoking have been identified as risk factors. The number of people with AMD is set to increase in line with the growing aging population in most developed countries. Currently, there is no effective treatment for AMD and GA, which are associated with significant and disabling loss of central vision.

The Age-Related Macular Degeneration market research report provides an overview of the risk factors, comorbidities, and global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year analytical forecast for total global sales of AMD. The total and forecasted prevalent drug sales of AMD are further segmented by age, sex, and stage in these markets.

Age-Related Macular Degeneration

To gain more information on the AMD market forecast, download a free report sample

Key Age-Related Macular Degeneration Market Drivers

The major driver for the AMD market growth will be the availability of therapies for geographic atrophy (GA), which will increase the number of treatable cases of AMD. Continual pursue of late-stage pipeline therapies for wAMD will be the strongest driver of the market in the 7MM. According to KOLs, Vabysmo’s potential to increase treatment intervals will become a favorable clinical feature in AMD treatment during the forecast period.

Key Age Segments in the Age-Related Macular Degeneration Market

The AMD market can be segmented based on age into 50-59 years, 60-69 years, 70-79 years, and above 80 years.

In 2021, for the 7MM combined, adults ages 60-69 years contributed the highest proportion of the diagnosed prevalent cases of chronic kidney disease followed by the age group 70–79 years.

Age-Related Macular Degeneration Analysis by Age

Age-Related Macular Degeneration Analysis by Age

For more age segment insights, download a free report sample

Key Sex Segments in the Age-Related Macular Degeneration Market

The AMD market can be segmented based on sex into men and women.

In the 7MM combined, the number of diagnosed prevalent cases of AMD was higher in women than in men in 2021. However, Italy had the highest gender difference in the number of diagnosed prevalent cases of AMD. Japan had the smallest variation in the number of diagnosed prevalent cases between men and women.

Age-Related Macular Degeneration Market Analysis by Sex

Age-Related Macular Degeneration Market Analysis by Sex

For more sex segment insights, download a free report sample

Key Stages in the Age-Related Macular Degeneration Market

The AMD market can be further divided into four stages: No AMD, Early AMD, and Intermediate AMD, and Advanced AMD. Advanced AMD can be sub categorized into two stages: Late Dry AMD, and Late Wet AMD.

Among the 7MM, Italy had the highest number of diagnosed prevalent cases of AMD in Early AMD stage followed by the US. This difference in stage-specific diagnosed prevalent cases might be driven by the varying stage-specific diagnosis rate in the markets.

Key Countries in the Global Sales for Age-Related Macular Degeneration Market

The US is anticipated to experience the fastest growth during the forecast period followed by France, Germany, Italy, Spain, the UK, and Japan.

Age-Related Macular Degeneration Market Analysis by Countries

Age-Related Macular Degeneration Market Analysis by Countries

For more country-wise insights, download a free report sample

Key Players in the Age-Related Macular Degeneration Market

Some of the key players in the AMD market are Roche, Apellis, Abbvie, Novartis, Genentech, and Outlook Therapeutics.

AMD Market report scope

  Market size (Year – 2021)  $7.3 billion
  Growth rate (CAGR)  >11%
  Forecast period 2021-2028
Key age segments 50-59 Years, 60-69 Years, 70-79 Years, and Above 80 Years
Key sex segments Men and Women
Key stage No AMD, Early AMD, and Intermediate AMD, and Advanced AMD
Key countries US, UK, France, Italy, Japan, Germany, Spain
  Key players Roche, Apellis, Abbvie, Novartis, Genentech, and Outlook Therapeutics

Scope 

  • Overview of Age-Related Macular Degeneration – including epidemiology, disease etiology, and management.
  • Topline AMD drugs market revenue, the annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
  • Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players, and market outlook for the US, 5U, and Japan over the 10-year forecast period.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global AMD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges

Key Highlights

AMD market will grow significantly during the forecast period, at a CAGR of 12.0%.

Late-stage pipeline therapies are anticipated to drive growth in the AMD market, with potential for first-to-market therapies for GA.

Development of cell-based and gene therapies represent a new paradigm of treatment modalities for AMD.

Reducing treatment burden is an important unmet need for wet AMD.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global AMD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
  • Track drug sales in the global AMD therapeutics market from 2021 to 2031.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

Regeneron

Bayer

Roche

Novartis

AbbVie

RegenxBio

Outlook Therapeutics

Kodiak Sciences

Opthea

Apellis Pharmaceuticals

Alkeus Pharmaceuticals

Iveric Bio

Table of Contents

| About GlobalData

1 Age-Related Macular Degeneration: Executive Summary

1.1 AMD market will grow significantly during the forecast period, reaching sales of $22.8 billion in 2031

1.2 Development of cell-based and gene therapies represent a new paradigm for AMD

1.3 Reducing treatment burden is an important unmet need for wet AMD

1.4 Treatment for geographic atrophy and dry AMD represent an important unmet need for AMD

1.5 Late-stage pipeline therapies are anticipated to drive growth in the AMD market

1.6 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Overview

3.1.2 Etiology

3.1.3 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources used

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD

4.4.4 Forecast assumptions and methods: total prevalent cases of GA

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, late wet AMD, and GA

4.5 Epidemiological forecast for AMD (2021–31)

4.5.1 Total prevalent cases of AMD

4.5.2 Age-specific total prevalent cases of AMD

4.5.3 Sex-specific total prevalent cases of AMD

4.5.4 Total prevalent cases of early AMD

4.5.5 Total prevalent cases of late AMD

4.5.6 Total prevalent cases of late dry AMD

4.5.7 Total prevalent cases of late wet AMD

4.5.8 Total prevalent cases of GA

4.5.9 Diagnosed prevalent cases of AMD

4.5.10 Age-specific diagnosed prevalent cases of AMD

4.5.11 Sex-specific diagnosed prevalent cases of AMD

4.5.12 Diagnosed prevalent cases of early AMD

4.5.13 Diagnosed prevalent cases of late AMD

4.5.14 Diagnosed prevalent cases of late dry AMD

4.5.15 Diagnosed prevalent cases of late wet AMD

4.5.16 Diagnosed prevalent cases of GA

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Longer-acting anti-VEGF therapies

7.3 Treatment for GA

7.4 Availability or accessibility of specialists and patient wait times

7.5 Less invasive drug formulations

7.6 Early diagnosis of patients and increasing awareness of AMD

8 R&D Strategies

8.1 Overview

8.1.1 Focus on the development of longer-acting therapies

8.1.2 Diversifying into gene therapies for AMD

8.1.3 Development of cell therapies for AMD

8.2 Clinical trials design

8.2.1 Consideration of endpoints for the whole spectrum of AMD

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist/Reviewers

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: AMD: key metrics in the 7MM

Table 2: Biological pathways associated with AMD risk genes

Table 3: The four-stage AREDS classification of AMD

Table 4: Symptoms of AMD

Table 5: Risk factors and comorbid conditions associated with AMD

Table 6: Treatment guidelines for AMD

Table 7: Top 10 deals by value, 2016–21

Table 8: AMD market – global drivers and barriers, 2021–2031

Table 9: Key events impacting sales for AMD in the US, 2021–2031

Table 10: AMD market – drivers and barriers in the US, 2021–2031

Table 11: Key events impacting sales for AMD in the 5EU, 2021–2031

Table 12: AMD market – drivers and barriers in the 5EU, 2021–2031

Table 13: Key events impacting sales for AMD in Japan, 2021–2031

Table 14: AMD market – drivers and barriers in Japan, 2021–2031

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

Figure 1: Global sales forecast by country for AMD in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in AMD during the forecast period

Figure 3: Competitive assessment of recently approved and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period

Figure 4: Comparison of the eye under normal vision and severe vision loss due to AMD

Figure 5: 7MM, total prevalence of AMD, men and women, ages ≥50 years, %, 2021

Figure 6: 7MM, diagnosed prevalence of AMD, men and women, ages ≥50 years, 2021

Figure 7: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD

Figure 8: 7MM, sources used to forecast the total prevalent cases of GA and diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD

Figure 9: 7MM, total prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021

Figure 10: 7MM, total prevalent cases of AMD by age, both sexes, N, 2021

Figure 11: 7MM, total prevalent cases of AMD, by sex, ages ≥50 years, N, 2021

Figure 12: 7MM, total prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021

Figure 13: 7MM, total prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021

Figure 14: 7MM, total prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021

Figure 15: 7MM, total prevalent cases of late wet AMD, both sexes, ages ≥50 years, N, 2021

Figure 16: 7MM, total prevalent cases of GA, both sexes, ages ≥50 years, N, 2021

Figure 17: 7MM, diagnosed prevalent cases of AMD, both sexes, ages ≥50 years, N, 2021

Figure 18: 7MM, diagnosed prevalent cases of AMD by age, both sexes, N, 2021

Figure 19: 7MM, diagnosed prevalent cases of AMD, by sex, ages ≥50 years, N, 2021

Figure 20: 7MM, Diagnosed prevalent cases of early AMD, both sexes, ages ≥50 years, N, 2021

Figure 21: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages ≥50 years, N, 2021

Figure 22: 7MM, diagnosed prevalent cases of late dry AMD, both sexes, ages ≥50 years, N, 2021

Figure 23: 7MM, diagnosed prevalent cases of late wet AMD, both sexes, ages ≥50 years, N, 2021

Figure 24: 7MM, diagnosed prevalent cases of GA, both sexes, ages ≥50 years, N, 2021

Figure 25: Amsler grid, as viewed by patients with normal vision and with wAMD

Figure 26: Unmet needs and opportunities in AMD

Figure 27: Overview of the development pipeline in AMD

Figure 28: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for AMD in the 7MM during the forecast period

Figure 29: Competitive assessment of recently approved agents and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period

Figure 30: Competitive assessment of the pipeline drugs benchmarked against the standard of care, Eylea

Figure 31: Analysis of the company portfolio gap in AMD during the forecast period

Figure 32: Global (7MM) sales forecast by country for AMD in 2021 and 2031

Figure 33: Sales forecast by disease subtype for AMD in the US in 2031

Figure 34: Sales forecast for GA in the US in 2031

Figure 35: Sales forecast by class for wAMD in the US in 2021 and 2031

Figure 36: Sales forecast by disease subtype in the 5EU in 2031

Figure 37: Sales forecast by class for wAMD in the 5EU in 2021 and 2031

Figure 38: Sales forecast by class for wAMD in Japan in 2021 and 2031

Frequently Asked Questions

Request a Free Sample
$10995

Can be used by individual purchaser only

$32985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.